评分≥2分,高危(年卒中风险4~18.2%),如无禁忌应使用华法林抗凝治疗,INR维持在2-3之间;
评分=1分,中危(年卒中风险2.8%),可使用华法林或阿司匹林进行抗凝治疗,取决于患者情况及医师的建议;
评分=0分,低危(年卒中风险1.9%),推荐使用阿司匹林325mg qd。
2006年ACC/AHA/ESC推荐用于房颤患者脑卒中危险分层,相比CHA2DS2-VASc,临床操作性强、简单易行。
                    
            1. Gage BF, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287-92.
        
        
                    
                        
                    
             2. Gage BF, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.
        
        
                    
                        
                    
             3. Go AS, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation:how well do randomized trials translate into clinical practice? JAMA. 2003;290(20):2685-92.